Hengrui Pharma, a Chinese biopharma company with clinical development programs across oncology, anesthesiology & pain management, autoimmune, and metabolic & cardiovascular diseases, has recently adopted Medidata Cloud, the Intelligent Platform for Life Sciences, to accelerate global drug research.
Hengrui selected the Medidata cloud platform in the third quarter of this year to unify data management and navigate international complexities. With Medidata’s unrivaled global expertise, the company will:
- Unify clinical trials and reduce risk with a single source for data entry
- Streamline study operations, planning and execution
- Automate reporting of adverse events
- Standardize data on the Medidata Cloud in support of global regulatory compliance requirements
“Medidata will enable us to make a bigger footprint globally and deliver smarter treatments to patients,” said Jianjun Zou, chief medical officer, Hengrui Pharma. “Only Medidata’s comprehensive offerings can support us as we expand our drug therapies to patients around the world. We are confident that Medidata’s exceptional cloud platform and deep understanding of both China and global regions will accelerate our drug development.”
Medidata’s end-to-end solutions provide a clear view into all clinical trial processes, including study planning and execution.
Filed Under: Drug Discovery and Development